Calico’s Barron to succeed Vallance at GSK

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said President of R&D Patrick Vallance will leave the company at the end of March 2018 to become the U.K. government's chief scientific adviser and head of the government's Office for Science, confirming multiple reports (see BioCentury Extra, Nov. 3).

Hal Barron will succeed Vallance and become GSK's CSO and president of R&D, effective Jan. 1. Barron is currently president of R&D at longevity company Calico LLC (South San Francisco, Calif.). GSK said Barron will be based in the U.S., and will operate from offices in both San Francisco and Stevenage, U.K. The San Francisco office will be focused on business development for R&D...